Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245385 · ClinicalTrials.gov registry record · Phase 2
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
A Phase 2 study, sponsored by Sun Pharmaceutical Industries Limited.
- Terminated
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03245385 is a Phase 2 study that was terminated before completion, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 20 participants.
The verdict
NCT03245385, a Phase 2 study, was terminated before completion, sponsored by Sun Pharmaceutical Industries Limited.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult patients with moderate to severe atopic dermatitis. At least 40 eligible patients with atopic dermatitis that satisfy all eligibility criteria will be enrolled into the study
Interventions
- DRUG Treatment with Halobetasol propionate 0.05% topical spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-07-24 |
| Est. Completion | 2018-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03245385
The ClinicalTrials.gov registry entry for NCT03245385 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Treatment with Halobetasol propionate 0.05% topical spray is the first listed.
NCT03245385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03245385 about?
NCT03245385 is a clinical study titled "Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis". This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult patients with moderate to severe atopic dermatitis. At least 40 eligible pa...
What is the current status of trial NCT03245385?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-07-24. Estimated completion is 2018-02-05.
What interventions are being tested in trial NCT03245385?
The interventions under investigation include: Treatment with Halobetasol propionate 0.05% topical spray (DRUG).
Who is sponsoring clinical trial NCT03245385?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.